Latest news with #AnacondaBiomed
Yahoo
18-06-2025
- Business
- Yahoo
ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke
Clinical Evidence Shows High Reperfusion and First Pass Success Rates with the Device BARCELONA, Spain, June 18, 2025--(BUSINESS WIRE)--ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union's health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU. The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The CE Mark approval is supported by a comprehensive body of evidence, including preclinical bench and animal studies, and clinical data from the recently published ANAIS study demonstrating high reperfusion and first-pass success rates. Further clinical validation is ongoing in the ATHENA trial, a prospective, multicenter randomized study systematically evaluating the impact of proximal flow arrest on reperfusion effectiveness, to support future regulatory submissions and commercialization efforts in the United States. "Receiving CE Mark approval is a pivotal achievement for ANACONDA Biomed that advances our mission to innovate in the interventional management of acute ischemic stroke," said Trent Reutiman, chief executive officer. "This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application." Dr. Marc Ribo, the co-founder of Anaconda Biomed, added, "Receiving CE Mark approval for ANA5 is deeply meaningful, as it represents the culmination of years of research, iteration, and belief in an idea that began at the bench. This is more than a regulatory milestone; it's the moment where innovation becomes impact. We're now gearing up to capture real-world data by collecting more invaluable insight into how ANA5 performs across diverse stroke centers and clinical realities." About ANA Funnel Catheter ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States. About Anaconda Biomed Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit and follow the company on LinkedIn. View source version on Contacts MEDIA CONTACT: Joe DuraesPazanga Health Communications jduraes@ 917-687-6419 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
11-06-2025
- Business
- Business Wire
Anaconda Biomed Appoints Dr. Charles Carignan as New Chairman of the Board of Directors
BARCELONA, Spain & MARIN, Calif.--(BUSINESS WIRE)-- Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, announced today the appointment of long-time medtech executive Charles (Chuck) Carignan, M.D., as chairman of the board. Dr. Carignan is joining the company at a critical time as enrollment progresses in the global investigational device exemption (IDE) ATHENA clinical trial, and additional work continues on building the company's pipeline of products. Dr. Carignan brings extensive clinical, product development, commercialization, and leadership expertise to the role. He has served on committees of the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development. Additionally, he has led multiple successful corporations, including being the founding president and CEO of NinePoint Medical, president and CEO of BionX Medical, and CEO of SoniVie Inc. Additional prior roles include executive vice president and chief medical officer at Novasys Medical, chief medical officer of Endosurgery at Boston Scientific, and vice president of clinical research and medical affairs at Conceptus, Inc. He currently serves as the executive chairman of Cairdac, chairman of SamanTree Medical, and a director of Biothea and Prothea. 'It is a privilege to welcome Chuck to Anaconda Biomed,' said Trent Reutiman, chief executive officer. 'With his leadership experience at Boston Scientific, numerous private venture-backed start-ups, and international government health agencies, Chuck brings a proven track record of developing and overseeing global healthcare companies. His operational and clinical insights will be invaluable as we continue to grow.' Dr. Carignan is joining the company at a critical time as enrollment progresses in the global investigational device exemption (IDE) ATHENA clinical trial, and additional work continues on building the company's pipeline of products. Dr. Carignan added, 'Beginning with the unique ANA Funnel Catheter technology, Anaconda has the opportunity to literally change the shape of the mechanical thrombectomy field. I am honored to join the board to actively contribute to the next phase of the company's successes by working closely with Trent and the rest of the board.' About ANA Funnel Catheter ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States or the European Union. About Anaconda Biomed Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit and follow the company on LinkedIn.
Yahoo
11-06-2025
- Business
- Yahoo
Anaconda Biomed Appoints Dr. Charles Carignan as New Chairman of the Board of Directors
BARCELONA, Spain & MARIN, Calif., June 11, 2025--(BUSINESS WIRE)--Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, announced today the appointment of long-time medtech executive Charles (Chuck) Carignan, M.D., as chairman of the board. Dr. Carignan brings extensive clinical, product development, commercialization, and leadership expertise to the role. He has served on committees of the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development. Additionally, he has led multiple successful corporations, including being the founding president and CEO of NinePoint Medical, president and CEO of BionX Medical, and CEO of SoniVie Inc. Additional prior roles include executive vice president and chief medical officer at Novasys Medical, chief medical officer of Endosurgery at Boston Scientific, and vice president of clinical research and medical affairs at Conceptus, Inc. He currently serves as the executive chairman of Cairdac, chairman of SamanTree Medical, and a director of Biothea and Prothea. "It is a privilege to welcome Chuck to Anaconda Biomed," said Trent Reutiman, chief executive officer. "With his leadership experience at Boston Scientific, numerous private venture-backed start-ups, and international government health agencies, Chuck brings a proven track record of developing and overseeing global healthcare companies. His operational and clinical insights will be invaluable as we continue to grow." Dr. Carignan is joining the company at a critical time as enrollment progresses in the global investigational device exemption (IDE) ATHENA clinical trial, and additional work continues on building the company's pipeline of products. Dr. Carignan added, "Beginning with the unique ANA Funnel Catheter technology, Anaconda has the opportunity to literally change the shape of the mechanical thrombectomy field. I am honored to join the board to actively contribute to the next phase of the company's successes by working closely with Trent and the rest of the board." About ANA Funnel Catheter ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States or the European Union. About Anaconda Biomed Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit and follow the company on LinkedIn. View source version on Contacts MEDIA CONTACT: Joe DuraesPazanga Health Communications jduraes@ 917-687-6419
